Janus-I Science will work with BARDA to develop a nanopore sequencing-based platform that can identify both routine and unexpected viruses in clinical specimens, and detect concomitant host responses, enabling identification of the causative agent of a viral infection and providing host response information without having any preconceived notions about the virus(es) involved. This project has the potential to revolutionize diagnostic testing by enabling a truly agnostic prognostic diagnostic, based on nanopore sequencing technologies, to be integrated into patient-care settings, informing caregivers to begin appropriate treatment and intervention at the earliest possible time point, saving lives and reducing morbidity.